Skip to main content
MANE
NYSE Life Sciences

Director John W. Childs Makes Substantial $72.5M Investment in Veradermics Following IPO

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$35.4
Mkt Cap
$1.303B
52W Low
$32
52W High
$40.11
52W Position info
11% above low
Off High info
12% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

MANE is trading near its 52-week low of $32 (11% above the low).

Summary

Director John W. Childs significantly increased his stake in Veradermics, Inc. through a $5 million open market purchase and the conversion of over $67 million in preferred stock into common shares, coinciding with the company's IPO.


Key Events · Ownership and Investor Activity · MANE

  • Director's Significant Investment

    Director John W. Childs acquired common stock totaling $72,539,260, representing a substantial increase in his holdings.

  • Open Market Purchase at IPO Price

    Childs made an open market purchase of 294,117 shares for $4,999,989 at $17.00 per share on February 5, 2026, aligning with the company's recent IPO pricing.

  • Preferred Stock Conversion

    Converted 1,907,889 shares of Series A, B, and C Convertible Preferred Stock into common stock, valued at $67,539,271, immediately prior to the IPO closing.

  • New Option Grant

    Received a grant of 51,525 stock options on February 3, 2026, which will fully vest on February 3, 2027.


Analysis · MANE · Life Sciences

This Form 4 filing reveals a substantial commitment from Director John W. Childs, who acquired common stock totaling over $72.5 million. This includes a direct open market purchase of nearly $5 million at the IPO price of $17.00 per share, alongside the automatic conversion of over $67 million in preferred stock into common shares. These transactions occurred immediately prior to or concurrent with the company's Initial Public Offering, as indicated by recent filings. Such a significant investment by a director, representing over 5% of the company's market capitalization, signals strong insider confidence in Veradermics' future prospects as it transitions to a public company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MANE was trading at $35.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $32.00 to $40.11. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Nov 13, 2026, 5:39 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $129.66
Real-time Price: $125.10 info
Change: -$4.56 (-4%) info
Market Cap: $5.289B info
MANE
Nov 10, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $148.44
Real-time Price: $125.10 info
Change: -$23.34 (-16%) info
Market Cap: $5.289B info
MANE
Nov 10, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $142.72
Real-time Price: $125.10 info
Change: -$17.62 (-12%) info
Market Cap: $5.289B info
MANE
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $142.00
Real-time Price: $125.10 info
Change: -$16.90 (-12%) info
Market Cap: $5.289B info
MANE
Nov 08, 2026, 6:00 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $139.33
Real-time Price: $125.10 info
Change: -$14.23 (-10%) info
Market Cap: $5.289B info